The official hand book for allergen immunotherapy in mite-allergy - causal treatment for perennial allergic airway diseases.
THE OFFICIAL HAND BOOK FOR ALLERGEN IMMUNOTHERAPY IN MITE-ALLERGY - CAUSAL TREATMENT FOR PERENNIAL ALLERGIC AIRWAY DISEASES. Arerugi. 2016 Jul;65(7):908-12 Authors: Nagata M PMID: 27545055 [PubMed - in process]
Peanut Oral Immunotherapy (POIT) is a novel and active form of treatment with multiple research studies supporting its efficacy and safety, but there are limited data available on patients ’ quality of life changes following successful desensitization. FDA recently approved the first drug for POIT commercial use.
Publication date: April 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 4Author(s): David Bernstein, Mike Tankersley, Hannah Russell
A medical society recently published recommendations to continue allergen immunotherapy during the COVID-19 pandemic. Is this the right decision?
A medical society recently published recommendations to continue allergen immunotherapy during the COVID-19 pandemic. Is this the right decision?Medscape Allergy &Immunology
AbstractPurpose of ReviewIdiopathic pulmonary hemosiderosis (IPH) is one of the rarest and least understood causes of pulmonary hemorrhage in children. Illustrated by a complex case presentation, we discuss the clinical manifestations, diagnosis, pathology, proposed etiologies, and treatment of this rare disease. We also compare IPH with anti-glomerular basement membrane antibody syndrome (anti-GBM disease), another rare causes of pediatric pulmonary hemorrhage.Recent FindingsRecent retrospective studies regarding IPH along with advanced immunotherapy have led to an improved understanding of how to best treat this conditio...
The Learning Early About Peanut Allergy (LEAP) trial and other studies suggest early peanut (PN) introduction prevents PN allergy in at-risk infants.1,2 In addition, PN-oral immunotherapy (PN-OIT) shows increased rates of sustained unresponsiveness in children4 mm.1 Guidelines recommend PN introduction or oral food challenge (OFC) in infants who have skin prick tests ≤7 mm and do not specifically address management of infants with SPTs>7 mm (or high PN-IgE levels).
Publication date: Available online 2 April 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Yuliya Afinogenova, Tamar Rubin, Sagar Patel, Rachel Powell, Janina Gilo, Morgan Denno, Gary Soffer, Jason Lee, Louis Mendelson, Jeffrey Factor
ConclusionThis work indicated the ability of LcZ to alleviate TM ‐induced food allergy and demonstrated the involvement of the tolerogenic immune cells and NF‐κB signaling pathway, indicating LcZ to be a potential immunomodulator and immunotherapy assistor.This article is protected by copyright. All rights reserved
AbstractPurpose of ReviewDiscuss optimal conditions for the office delivery of allergy immunotherapy with regard to medical personnel supervision and techniques for sterility of antigen vial preparation and delivery.Recent FindingsThe revised USP 797 pharmaceutical compounding guidelines, combined with allergen extract preparation directions provide clear instructions for the general supervision and oversight of allergen preparation for immunotherapy.SummarySterility of antigen vial preparation and supervision of office personnel delivering and preparing allergy immunotherapy are critical points of competency allowing for ...
Conclusions.SCIT with house dust mixture of ROXALL Medicina España S.A. seems to have an acceptable tolerability profile, induces blocking IgG and decreases skin reactivity. PMID: 32223886 [PubMed - as supplied by publisher]